GlassScriptPhysician profile
Caitlin G Cecil
NPI 1992106322
$10,479.23
in general payments reported to CMS, 2019-2025
35 companies · $4,342 in 2025
The $4,342 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $280 · 2022: $304 · 2023: $2,151 · 2024: $3,403 · 2025: $4,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,841 · Education: $53.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,840.75 |
| Education | $53.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,168.21 | 2021-2025 | |
| Janssen Biotech, INC. | $1,786.36 | 2021-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,222.92 | 2021-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $790.40 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $677.33 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Ardelyx, INC. | $543.94 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $439.04 | 2023-2025 | |
| Pfizer INC. | $355.49 | 2021-2025 | |
| Lilly USA, LLC | $332.12 | 2023-2025 | Omvoh |
| Qol Medical, LLC | $245.71 | 2021-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $216.71 | 2023-2025 | Dupixent |
| Madrigal Pharmaceuticals | $187.53 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $185.14 | 2023-2025 | Linzess |
| Celltrion USA INC. | $153.20 | 2024-2025 | Vegzelma, Zymfentra |
| Merck Sharp & Dohme LLC | $149.59 | 2023-2024 | Dificid |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $144.66 | 2024-2025 | |
| Celgene Corporation | $124.20 | 2023-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $119.70 | 2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $109.81 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $65.31 | 2023 | |
| Aimmune Therapeutics, INC. | $64.08 | 2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $50.30 | 2024-2025 | Iqirvo |
| Sandoz INC. | $48.72 | 2024 | Hyrimoz |
| Novo Nordisk INC | $42.85 | 2025 | Wegovy |
| Amgen INC. | $41.78 | 2022-2023 | Amjevita, Avsola |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.54 | 2023 | Cyltezo |
| Fresenius Kabi USA, LLC | $30.46 | 2023 | Idacio |
| Orphalan INC | $25.76 | 2024 | Cuvrior |
| Gilead Sciences, INC. | $25.36 | 2025 | |
| Digestive Care, INC. | $19.16 | 2023 | Pertzye |
| Supernus Pharmaceuticals, INC. | $17.99 | 2025 | Qelbree |
| Organon LLC | $17.40 | 2024 | |
| Evoke Pharma, INC. | $17.11 | 2025 | |
| Alnylam Pharmaceuticals INC. | $14.62 | 2024 | Givlaari |
| Albireo Pharma, INC. | $13.73 | 2024 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Cecil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.